NR1H4 and metabolic dysfunction-associated steatotic liver disease: Lastly, Farnesoid X receptor (FXR) agonists, such as obeticholic acid (OCA), appear to be a hopeful medication for NAFLD treatment because of their anti-inflammatory, insulin-sensitizing, anti-steatotic, and anti-fibrotic effects, which have been demonstrated in animal models [144].